APO RESEARCH · REPORT
Peptide Cancer Vaccine
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
Product & engineering
Understand the product.
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
Selected research
Industry Research
Peptide Cancer Vaccine Industry Research Report 2026
Market perspective
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
Peptide Cancer Vaccine can be used for Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others cancers. The most proportion research of Peptide Cancer Vaccine is about Melanoma, and the proportion is about 40%.
USA is the largest consumption place, with a consumption market share nearly 53% . Following USA, Europe is the second largest consumption place with the consumption market share of 31%.
Read the full market overview
Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals and OncoTherapy Science are the key manufacturters of Peptide Cancer Vaccine.
Report Scope
This report quantifies the global Peptide Cancer Vaccine market in terms of revenue (US$ million) and, where applicable, sales volume (K Doses), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Doses) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Peptide Cancer Vaccine Market by Company
Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Sellas
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science
Peptide Cancer Vaccine Segment by Pipeline
ITK-1
GRN-1201
TPIV200
TPIV110
UV1
Galinpepimut-S
TARP 27-35
HER-Vaxx
Vx-001
Others
Peptide Cancer Vaccine Segment by Application
Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
Peptide Cancer Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Cancer Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Cancer Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Cancer Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Peptide Cancer Vaccine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Peptide Cancer Vaccine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Peptide Cancer Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by pipeline, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- ITK-1
- GRN-1201
- TPIV200
- TPIV110
- UV1
- Galinpepimut-S
- TARP 27-35
- HER-Vaxx
- Vx-001
- Others
Applications
- Breast Cancer
- Lung Cancer
- Melanoma
- Prostate Cancer
- Others
Companies covered
- Boston Biomedical
- Ultimovacs
- BrightPath Biotherapeutics
- TapImmune
- Immatics
- Sellas
- Imugene
- VAXON Biotech
- Generex Biotechnology
- ISA Pharmaceuticals
- OncoTherapy Science
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Peptide Cancer Vaccine Market Size (2021-2032)
- 2.2.2 Global Peptide Cancer Vaccine Sales (2021-2032)
- 2.2.3 Global Peptide Cancer Vaccine Market Average Price (2021-2032)
- 2.3 Peptide Cancer Vaccine by Pipeline
- 2.3.1 Market Value Comparison by Pipeline (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 ITK-1
- 2.3.3 GRN-1201
- 2.3.4 TPIV200
- 2.3.5 TPIV110
- 2.3.6 UV1
- 2.3.7 Galinpepimut-S
- 2.3.8 TARP 27-35
- 2.3.9 HER-Vaxx
- 2.3.10 Vx-001
- 2.3.11 Others
- 2.4 Peptide Cancer Vaccine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Breast Cancer
- 2.4.3 Lung Cancer
- 2.4.4 Melanoma
- 2.4.5 Prostate Cancer
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Peptide Cancer Vaccine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Peptide Cancer Vaccine Sales (K Doses) of Manufacturers (2021-2026)
- 3.3 Global Peptide Cancer Vaccine Revenue of Manufacturers (2021-2026)
- 3.4 Global Peptide Cancer Vaccine Average Price by Manufacturers (2021-2026)
- 3.5 Global Peptide Cancer Vaccine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Peptide Cancer Vaccine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Peptide Cancer Vaccine, Product Type & Application
- 3.8 Global Manufacturers of Peptide Cancer Vaccine, Established Date
- 3.9 Global Peptide Cancer Vaccine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Boston Biomedical
- 4.1.1 Boston Biomedical Company Information
- 4.1.2 Boston Biomedical Business Overview
- 4.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Boston Biomedical Peptide Cancer Vaccine Product Portfolio
- 4.1.5 Boston Biomedical Recent Developments
- 4.2 Ultimovacs
- 4.2.1 Ultimovacs Company Information
- 4.2.2 Ultimovacs Business Overview
- 4.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Ultimovacs Peptide Cancer Vaccine Product Portfolio
- 4.2.5 Ultimovacs Recent Developments
- 4.3 BrightPath Biotherapeutics
- 4.3.1 BrightPath Biotherapeutics Company Information
- 4.3.2 BrightPath Biotherapeutics Business Overview
- 4.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Product Portfolio
- 4.3.5 BrightPath Biotherapeutics Recent Developments
- 4.4 TapImmune
- 4.4.1 TapImmune Company Information
- 4.4.2 TapImmune Business Overview
- 4.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 TapImmune Peptide Cancer Vaccine Product Portfolio
- 4.4.5 TapImmune Recent Developments
- 4.5 Immatics
- 4.5.1 Immatics Company Information
- 4.5.2 Immatics Business Overview
- 4.5.3 Immatics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Immatics Peptide Cancer Vaccine Product Portfolio
- 4.5.5 Immatics Recent Developments
- 4.6 Sellas
- 4.6.1 Sellas Company Information
- 4.6.2 Sellas Business Overview
- 4.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sellas Peptide Cancer Vaccine Product Portfolio
- 4.6.5 Sellas Recent Developments
- 4.7 Imugene
- 4.7.1 Imugene Company Information
- 4.7.2 Imugene Business Overview
- 4.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Imugene Peptide Cancer Vaccine Product Portfolio
- 4.7.5 Imugene Recent Developments
- 4.8 VAXON Biotech
- 4.8.1 VAXON Biotech Company Information
- 4.8.2 VAXON Biotech Business Overview
- 4.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 VAXON Biotech Peptide Cancer Vaccine Product Portfolio
- 4.8.5 VAXON Biotech Recent Developments
- 4.9 Generex Biotechnology
- 4.9.1 Generex Biotechnology Company Information
- 4.9.2 Generex Biotechnology Business Overview
- 4.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Generex Biotechnology Peptide Cancer Vaccine Product Portfolio
- 4.9.5 Generex Biotechnology Recent Developments
- 4.10 ISA Pharmaceuticals
- 4.10.1 ISA Pharmaceuticals Company Information
- 4.10.2 ISA Pharmaceuticals Business Overview
- 4.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Product Portfolio
- 4.10.5 ISA Pharmaceuticals Recent Developments
- 4.11 OncoTherapy Science
- 4.11.1 OncoTherapy Science Company Information
- 4.11.2 OncoTherapy Science Business Overview
- 4.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 OncoTherapy Science Peptide Cancer Vaccine Product Portfolio
- 4.11.5 OncoTherapy Science Recent Developments
5 Global Peptide Cancer Vaccine Market Scenario by Region
- 5.1 Global Peptide Cancer Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Peptide Cancer Vaccine Sales by Region: 2021-2032
- 5.2.1 Global Peptide Cancer Vaccine Sales by Region: 2021-2026
- 5.2.2 Global Peptide Cancer Vaccine Sales by Region: 2027-2032
- 5.3 Global Peptide Cancer Vaccine Revenue by Region: 2021-2032
- 5.3.1 Global Peptide Cancer Vaccine Revenue by Region: 2021-2026
- 5.3.2 Global Peptide Cancer Vaccine Revenue by Region: 2027-2032
- 5.4 North America Peptide Cancer Vaccine Market Facts & Figures by Country
- 5.4.1 North America Peptide Cancer Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Peptide Cancer Vaccine Sales by Country (2021-2032)
- 5.4.3 North America Peptide Cancer Vaccine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Peptide Cancer Vaccine Market Facts & Figures by Country
- 5.5.1 Europe Peptide Cancer Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Peptide Cancer Vaccine Sales by Country (2021-2032)
- 5.5.3 Europe Peptide Cancer Vaccine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Peptide Cancer Vaccine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Peptide Cancer Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Peptide Cancer Vaccine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Peptide Cancer Vaccine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Peptide Cancer Vaccine Market Facts & Figures by Country
- 5.7.1 South America Peptide Cancer Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Peptide Cancer Vaccine Sales by Country (2021-2032)
- 5.7.3 South America Peptide Cancer Vaccine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Peptide Cancer Vaccine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Peptide Cancer Vaccine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Peptide Cancer Vaccine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Pipeline
- 6.1 Global Peptide Cancer Vaccine Sales by Pipeline (2021-2032)
- 6.1.1 Global Peptide Cancer Vaccine Sales by Pipeline (2021-2032) & (K Doses)
- 6.1.2 Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2021-2032)
- 6.2 Global Peptide Cancer Vaccine Revenue by Pipeline (2021-2032)
- 6.2.1 Global Peptide Cancer Vaccine Sales by Pipeline (2021-2032) & (US$ Million)
- 6.2.2 Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2021-2032)
- 6.3 Global Peptide Cancer Vaccine Price by Pipeline (2021-2032)
7 Segment by Application
- 7.1 Global Peptide Cancer Vaccine Sales by Application (2021-2032)
- 7.1.1 Global Peptide Cancer Vaccine Sales by Application (2021-2032) & (K Doses)
- 7.1.2 Global Peptide Cancer Vaccine Sales Market Share by Application (2021-2032)
- 7.2 Global Peptide Cancer Vaccine Revenue by Application (2021-2032)
- 7.2.1 Global Peptide Cancer Vaccine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Peptide Cancer Vaccine Revenue Market Share by Application (2021-2032)
- 7.3 Global Peptide Cancer Vaccine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Peptide Cancer Vaccine Value Chain Analysis
- 8.1.1 Peptide Cancer Vaccine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Peptide Cancer Vaccine Production Mode & Process
- 8.2 Peptide Cancer Vaccine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Peptide Cancer Vaccine Distributors
- 8.2.3 Peptide Cancer Vaccine Customers
9 Global Peptide Cancer Vaccine Analyzing Market Dynamics
- 9.1 Peptide Cancer Vaccine Industry Trends
- 9.2 Peptide Cancer Vaccine Industry Drivers
- 9.3 Peptide Cancer Vaccine Industry Opportunities and Challenges
- 9.4 Peptide Cancer Vaccine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst